GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BridgeBio Pharma Inc (FRA:2CL) » Definitions » Sale Of Investment

BridgeBio Pharma (FRA:2CL) Sale Of Investment : €187.8 Mil (TTM As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is BridgeBio Pharma Sale Of Investment?

BridgeBio Pharma's sale of investment for the three months ended in Jun. 2024 was €51.1 Mil. It means BridgeBio Pharma gained €51.1 Mil from selling investments. BridgeBio Pharma's sale of investment for the trailing twelve months (TTM) ended in Jun. 2024 was €187.8 Mil.

Compared with last quarter (€58.2 Mil in Mar. 2024 ), BridgeBio Pharma gained less money from selling investments in Jun. 2024 (€51.1 Mil).


BridgeBio Pharma Sale Of Investment Historical Data

The historical data trend for BridgeBio Pharma's Sale Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BridgeBio Pharma Sale Of Investment Chart

BridgeBio Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sale Of Investment
Get a 7-Day Free Trial - 204.79 422.18 502.70 177.08

BridgeBio Pharma Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Sale Of Investment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 44.61 51.44 27.14 58.17 51.10

BridgeBio Pharma Sale Of Investment Calculation

Sale of Investments represents cash inflow on the sale of investments in securities.

Sale Of Investment for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €187.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BridgeBio Pharma Sale Of Investment Related Terms

Thank you for viewing the detailed overview of BridgeBio Pharma's Sale Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.


BridgeBio Pharma Business Description

Traded in Other Exchanges
Address
3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology.

BridgeBio Pharma Headlines

No Headlines